EPO and myelodysplastic syndrome: Luspatercept (ACE-536) is a novel agent responsible for stimulating the late stage of erythropoiesis through a different mechanism from erythropoietin (196, 197), and is expected to be effective in MDS patients who are refractory to erythropoiesis stimulating agents (ESA).